Migdal Insurance: Why The Insurance Subsidiary Board Became A Strategic Bottleneck

What This Follow-Up Is Isolating

The main article argued that Migdal's 2025 earnings recovery still had to pass through regulation and solvency before it could become real capital flexibility. This follow-up isolates a different layer of the same story: the board of Migdal Insurance itself. The filing sequence from January 9 to March 4, 2026 shows that the issue was no longer just about replacing Prof. Amir Barnea, or closing the Roni Gamzu episode. The deeper issue was who gets to determine the insurance subsidiary's board composition, by what process, and at what distance from the holding company.

There was one real improvement by the end of that sequence. Gamzu dropped out, the four-candidate plan and 12-seat structure were cut back to two candidates, and on March 4, 2026 Migdal Insurance's own board moved forward with Raviv Zoler's appointment as a director, with a new chair expected to be chosen only after that appointment becomes effective. But the path to that narrower outcome was costly. On January 19, 2026 the supervisor had already written that Migdal Insurance had been operating for about a year under uncertainty over board composition and the identity of its chair, while two directors were serving under temporary appointments. On March 3, 2026 the language became sharper still: the supervisor wrote that the non-renewal process for Avraham Doten lacked validity, was not anchored in law or in Migdal Insurance's articles, and harmed the subsidiary's independence.

That is the bottleneck. In a regulated insurer, the board is not decorative governance. It is where risk oversight, appointments, supervisory trust, and capital policy all meet. Once the supervisor describes the process itself as harming stability, proper management, and independence, the story stops being a personal dispute and becomes a strategic constraint on execution.

The Timeline: From One Candidate To A Fight Over The Rules

This chart is small, but it explains a lot. On February 11 the holding company pushed a broader plan that would effectively have taken the board to 12 members. Only 11 days later it had already retreated to two candidates and a 9-member structure. That does not read like orderly implementation of a settled plan. It reads like course correction under regulatory pressure.

What Actually Got Stuck

The problem was not just the chair identity

One of the key findings in this sequence is that Gamzu's withdrawal did not solve the issue. On January 9, 2026 he stepped away from the path to become a director at Migdal Insurance, and the holding-company board said it would consider another candidate. If the conflict had been centered only on one person, that should have marked the start of stabilization. Instead, only ten days later the supervisor sent a broader and harsher letter demanding an immediate response on the staffing of the Migdal Insurance board and the chair role.

The implication is that the friction was not primarily personal. Gamzu may have been the visible flashpoint, but not the core problem. The real bottleneck was the channel through which the holding company was trying to shape the subsidiary board and chair succession while the supervisor was already treating that process as a source of instability.

The dispute moved from names to process legitimacy

This is where the annual report gives the sharpest clue. In September 2025 the company described the general meeting decision at Migdal Insurance as consistent with legal requirements and with the desired board composition. By March 2026, the same thread was being described very differently. The supervisor wrote that the holding-company board, acting as the general meeting of Migdal Insurance, was impairing the process of setting the desired composition, was not aligned with Migdal Insurance's own decision that the desired board should have 9 members, and had used a process that was not grounded in law or in Migdal Insurance's articles.

That is a material gap. It means the disagreement was no longer about pace, or about the quality of one candidate versus another. It was about the legitimacy of the mechanism itself. Once the regulator uses terms such as "lack of validity," "not anchored in law," "harms proper management," and "harms independence," it is no longer criticizing only the outcome. It is criticizing how decisions are being made.

In an insurer, that is already strategic friction

In industrial or software companies, board tension can sometimes be treated as unpleasant background noise. In an insurer, it works differently. In January 2026 the supervisor wrote that Migdal Insurance had been operating for about a year under uncertainty over board composition and the identity of its chair, in a way that harmed stability and proper management. In March 2026 he went further and tied the Doten non-renewal path to harm to the subsidiary's independence and to a recurring pattern of weak transparency toward the authority.

The important point is that the annual report does not bury this in a footnote. It devotes a dedicated governance section to board changes and supervisory letters, and then updates that section through post-balance-sheet developments up to March 4, 2026. That is already a sign that this is no longer passing filing noise. It is part of the framework through which Migdal's execution capacity has to be read.

There is also a broader strategic layer here. The same annual report says that after the reporting period, in March 2026, the boards of Migdal Insurance and Migdal Capital Raising approved in principle a possible issuance of an Additional Tier 1 instrument, subject to the supervisor's approval. That does not create a formal causal link between the supervisory letters on board composition and the capital move. But it does clarify that both board appointments and capital actions pass through the same regulatory approval gate. That is why prolonged friction over governance process is not only a reputational problem. It sits at the junction where management, capital, and supervisory trust meet.

What Changed In February, And Why It Was Not Just A Technical Retreat

The move from the February 11 plan to the February 22 plan is probably the sharpest analytical point in the entire sequence. On February 11 the company tried to advance four candidates, in a structure that would have taken Migdal Insurance's board to 12 members together with another independent director. By February 22 it had already cut the plan back to only two candidates, stated that the board would remain at 9 members for now, and delayed the other two candidates until after a new chair enters the role.

That was not a technical retreat. It was a practical admission that the broader move could not be implemented under the power structure that had formed. In early February the attempt was to reshape both the board and the chair-succession path at once. By late February the company had moved to a more defensive structure: first bring in two names, keep the board at 9, recommend Zoler for the chair, and return the actual choice of chair to Migdal Insurance's own board, subject to supervisory non-objection.

That is an important change of direction, because it shows that the solution that emerged by the end of the sequence was not more freedom for the holding company. It was less. As regulatory pressure intensified, the center of gravity had to move back toward the insurance subsidiary and its own board.

What Has To Happen For The Bottleneck To Clear

The first step is obvious. Raviv Zoler's appointment as a director at Migdal Insurance has to become effective, and only then does Migdal Insurance's board need to choose a new chair from among its members, subject to supervisory non-objection. Without that, March 2026 remains only another round in the file, not a closing point.

The second step matters just as much. Temporary appointments need to become a stable structure. In January 2026 the supervisor wrote that two directors were serving under temporary appointments. So even if the chair question is resolved, the read will remain cautious as long as the board does not look closed, stable, and less dependent on interim solutions.

The third step is procedural. The company will have to show that future board composition is being set in a path that is acceptable both to Migdal Insurance itself and to the supervisor, without returning to structures the regulator sees as harming the subsidiary's independence or lacking legal footing. Until that issue is settled, every future appointment will sit on the same weak foundation.

Conclusion

The right reading of the January to March 2026 sequence is that Migdal Insurance's board became a strategic bottleneck not because one name was missing, but because the boundary between the holding company, the insurance subsidiary, and the supervisor had eroded. Gamzu's withdrawal did not close the episode. It only exposed that the real dispute was over who gets to shape the board, by what process, and how much independence the insurance subsidiary is allowed to preserve.

The less bad news is that by the end of the sequence a narrower structure did emerge: 9 directors instead of 12, two candidates instead of four, and a return of the chair decision to Migdal Insurance's own board after Zoler's appointment is completed. But that is still the beginning of stabilization, not the end of it. As long as the supervisor continues to describe the process as harming proper management, stability, and independence, it is hard to dismiss the board story as ordinary corporate noise. At Migdal in early 2026, this is already a real execution constraint.